Paul S. McCabe, 1 Matthew J. Parkes, 2 Nasimah Maricar, 2 Charles E. Hutchinson, 3 Anthony Freemont, 1 Terence W. O'Neill, 4 and David T. Felson 5 Objective. Osteoarthritis (OA) is a disease with a significant inflammatory component. The aim of this analysis was to determine the relationship between synovial fluid (SF) white blood cell (WBC) count and 2 parameters: disease severity and the reduction in knee pain after intraarticular (IA) steroid injection.
Methods. Subjects with painful knee OA were recruited for participation in an open-label study of IA steroid therapy. Information was obtained about knee pain using the Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire, and a proportion of subjects underwent magnetic resonance imaging (MRI). Prior to injection with 80 mg methylprednisolone acetate, the index knee joint was aspirated and the fluid obtained was forwarded for assessment of SF WBC count.
Results. Information on SF WBC count was available for 55 subjects. An increase in WBC count category (£100, 101-250, and 251-1,000 cells/mm 3 ) was associated with an increase in synovial tissue volume (P 5 0.028) and with other MRI-based measures of disease severity. Also, with each increase in SF WBC count category, there was a greater reduction in KOOS score after steroid injection (for WBC count of £100 cells/mm 3 Conclusion. Although all participants in the analysis had SF WBC counts within the "normal" range, total SF WBC count appears to be a biomarker for synovitis on MRI and may also predict response to antiinflammatory treatment.
Osteoarthritis (OA) is increasingly recognized as a disease with a significant inflammation component (1) . Recent studies suggest that up to 90% of subjects with knee OA have evidence of synovial thickening on magnetic resonance imaging (MRI) (2) . Synovial thickening on MRI has been shown in persons with symptomatic knee OA to be correlated with macroscopic scoring of synovitis (r 5 0.61) and histologically with infiltration of inflammatory cells into the subsurface layers of synovium (r 5 0.54) (3). We have shown recently in symptomatic knee OA that there is a correlation between synovial tissue volume and pain severity (4) .
Synovial fluid (SF) white blood cell (WBC) count has long been recognized to have utility in the assessment and diagnosis of arthritis (5, 6) . However, SF in OA is typically designated as a noninflammatory fluid (defined ISRCTN Freemont and Abdellatif as a WBC count of ,1,000 cells/mm 3 ) (7) without any further stratification within that range.
Intraarticular (IA) steroid injections are frequently used to treat symptoms in knee OA, but in clinical practice the response to therapy is mixed; some patients experience dramatic improvement in pain after injection, while others derive little if any benefit. A wide variety of putative predictors of response to IA steroid injections have been evaluated, although none have been found to be a reliable predictor of treatment response (for review, see ref. 8) . Surprisingly, particularly given the frequency with which SF is obtained in research and clinical practice, the role of SF WBC count as a potential predictor of treatment response or as a marker of disease activity has not been fully evaluated.
We hypothesized that higher SF WBC counts within the noninflammatory range, as a marker of lowgrade inflammation, would be associated with increased synovial tissue volume and pain and might identify persons more likely to respond to an antiinflammatory treatment. Using data from a recent open-label trial of IA corticosteroid injections (4), the aim of this study was to determine the clinical and structural correlates of SF WBC count in those with symptomatic knee OA.
SUBJECTS AND METHODS
One hundred twenty men and women age $40 years were recruited for participation in an open-label study assessing the efficacy of IA corticosteroid injection in knee OA and including assessment of structural change by MRI. Criteria for eligibility, including inclusion and exclusion criteria, have been published previously (1) . We studied 1 knee per participant, with the requirement that subjects had to have had at least moderate knee pain for 48 hours in the preceding 2 weeks or a score of .7 on questions P2-P9 of the Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire (9) . Eighty additional subjects participated in an extension study which, because of costs, did not use MR imaging but did not differ otherwise. Participants were required to have painful primary knee OA evidenced by changes on radiography, MRI, or arthroscopy (Kellgren/Lawrence [K/L] grade of $2 [10] or typical changes of OA with at least cartilage loss).
At baseline, participants completed questionnaires, including the KOOS as well as the visual analog scale (VAS) for pain during a nominated activity that the participant found most painful (nominated activity VAS). Participants in the main study, although not in the extension study, underwent contrastenhanced MRI (CE-MRI) followed by arthrocentesis and injection of 80 mg methylprednisolone acetate without local anesthetic and were advised to rest for a day after the injection. Subjects were seen again usually within 2 weeks, at which time they completed another KOOS questionnaire and nominated activity VAS and underwent another CE-MRI. Participants provided written informed consent, and this study was approved by the Leicestershire Multicentre Research Ethics Committee (reference 09/ H0402/107). SF analysis. During arthrocentesis, SF, if present, was withdrawn and decanted into a 2-ml lithium heparin tube. SF samples not immediately transferred to the laboratory were stored at 58C, and analysis was performed within 48 hours. Samples were processed at an experienced laboratory that provided a regional SF analysis service. Analysis was performed using the method described by Denton (11) , with the WBC count determined using a Fuchs-Rosenthal counting chamber following staining with 0.01% weight/volume methyl violet 6b in normal saline or, depending on equipment availability, using an automated Cellometer Vision cytometer (PeqLab) following staining with 0.002% w/v acridine orange solution. Participants with an SF WBC count of .1,500 cells/mm 3 (n 5 2) were withdrawn from the trial due to concerns that they might have primary inflammatory arthritis.
MRI assessment. At baseline and follow-up, participants in the MRI study underwent a CE-MRI of the knee performed using a 3T Philips MRI machine. Synovial tissue volume was determined by manual segmentation of the synovial tissue layer on the sagittal postcontrast T1-weighted fat-suppressed image by a single observer, followed by computer image analysis as described previously (4) . The intraclass correlation coefficient for synovial volume was 0.94 (P , 0.001) (4) . A subsample of subjects (n 5 101 in the MRI study) also underwent semiquantitative assessment of cartilage loss (14 areas scored 0-6, maximum score 84), osteophytes (14 areas scored 0-7, maximum score 98), and bone marrow lesions (15 areas scored 0-3, maximum score 45) by an experienced radiologist using the Whole-Organ Magnetic Resonance Imaging Score (WORMS) (2, 12) . Semiquantitative assessment of synovitis was performed at 7 regions, each scored from 0 to 3 as described by Roemer et al (2) . Intrareader reliability of the same reader reevaluating 19 films after a time interval was calculated and yielded weighted kappa values of 0.63-0.88 depending on the feature. Statistical analysis. Participants were divided into tertiles based on SF WBC count: those with #100 cells/mm 3 , those with 101-250 cells/mm 3 , and those with 251-1,000 cells/ mm 3 . At baseline, depending on the distribution of the variable, we used parametric (analysis of variance) or nonparametric (Kruskal-Wallis) tests to determine the significance of differences in symptoms and structural change between groups. Chi-square tests were used to determine the significance of differences in categorical data. We used linear regression to assess the association between SF WBC count and within-person change in pain and synovial tissue volume. Statistical analysis was performed using Stata software, version 13.1 (StataCorp).
RESULTS
Subject characteristics. An SF aspirate was obtained from 93 participants, and analysis was performed on SF samples from 67 of these participants, yielding a median synovial fluid volume of 4 ml (interquartile range [IQR] 2-9). Between subjects who did and those who did not have their SF analyzed, there was no significant difference in age (mean 62.6 years versus 66.6 years or pain at baseline (mean KOOS score of 45.7 versus 44.2; mean nominated activity VAS score of 7.0 versus 6.8, respectively). The laboratory reported a precise SF WBC count for 47 samples (70.1% of all SF samples analyzed), with the remainder reported as either ,100 cells/mm 3 (n 5 8, 11.9%) or ,500 cells/mm 3 (n 5 12, 17.9%). Due to the uncertainty about the WBC count estimate, samples reported as ,500 cells/mm 3 were excluded from further analysis, leaving SF samples from 55 subjects (37 for whom there were MRI findings and 18 for whom there were not). As shown in Table 1 , the mean 6 SD age of those 55 subjects was 61.0 6 10.3 years, and 65.5% were men. The majority of participants had a K/L grade of 2 or 3. The mean 6 SD KOOS score at baseline was 46.6 6 15.6 ( Table 1) .
Association between SF WBC count, knee pain, and structural parameters. We found no significant association between SF WBC count and age, pain at baseline as assessed by the KOOS or nominated activity VAS, or disease severity as assessed by K/L grade. In contrast, there were significant increases in synovial tissue volume and in whole-knee semiquantitative scores for synovitis, cartilage loss, and bone marrow lesions with increasing WBC count category. However, there was no association with osteophyte score ( Table 2) . SF WBC count and change in pain and structure following steroid injection. Subjects were reviewed a median of 8 days (IQR 8-14 days) following the baseline assessment. Compared to those with WBC counts of #100 cells/mm 3 , there were greater within-person reductions in the KOOS score in those with WBC counts of 101-250 cells/mm 3 (b coefficient 0.279, P 5 0.049) and in those with WBC counts of 251-1,000 cells/mm 3 (b coefficient 0.320, P 5 0.024) ( Table 3 ). Further adjustment for the amount of synovial fluid removed did not affect the significance of the results. A similar trend toward greater pain reduction with increasing SF WBC count was observed for the nominated activity VAS score, but this did not reach statistical significance (with referent of #100 cells/mm 3 : for 101-250 cells/mm 3 , b coefficient 20.242, P 5 0.107; for 251-1,000 cells/mm 3 , b coefficient 20.272, P 5 0.072). Increasing WBC count was associated with greater within-person change in synovitis measured both quantitatively and semiquantitatively, although the association did not attain statistical significance.
DISCUSSION
This is the first study of the association between SF WBC count and knee joint structure assessed by MRI in knee OA. Even though all participants in the analysis had SF WBC counts within the "normal" range, our data showed that increasing SF WBC count was correlated with more severe knee OA and also with synovitis as defined by synovial tissue volume. Additionally, those with a higher SF WBC count at baseline experienced greater reduction in knee pain following an IA steroid injection.
Our finding of an association between SF WBC count and synovitis at baseline assessed either quantitatively or semiquantitatively is consistent with findings of an association between increased SF WBC count and other measures of inflammation in primary inflammatory arthritides (5, 6, 11, 13) . We found no association of SF WBC count with the K/L grade, although the number of subjects with more severe disease (n 5 3 with a K/L grade of 4) was small. To our knowledge, only 2 other studies have looked at the association between SF WBC count and K/L grade; neither showed evidence of any association (14, 15) .
We also identified an association between increasing baseline SF WBC count and reduction in pain assessed by the KOOS score following IA steroid injection. Those in the highest tertile of SF WBC count experienced a .2fold reduction in pain compared to those in the lowest tertile, assessed by either the KOOS or the nominated activity VAS. These findings suggest that SF WBC count could have a role in predicting treatment response. This or other measures of synovial inflammation may even facilitate treatment stratification. One previous study showed no association between baseline WBC count and change in pain on a VAS following IA steroid injection in knee OA, although only 16 subjects were studied (15) .
A number of limitations need to be considered when interpreting our data. This study was a post hoc analysis using existing data, and the number of participants included in this analysis was small (n 5 55, with MRI findings for 37). Some caution is therefore required in interpretation. Our primary rationale for assessing SF WBC count was to identify and exclude participants with an alternate diagnosis. Therefore, during the conduct of this study, we accepted reporting of SF WBC count as either ,100 cells/mm 3 or ,500 cells/mm 3 , as these were below the exclusion criteria cutoff. However, the manner in which SF WBC count was reported led to a reduction in our sample size, due to exclusion of participants with WBC counts reported as ,500 cells/mm 3 , and prevented analysis using SF WBC count as a continuous variable. Both of these limitations served to reduce the power of the study. Further studies with larger numbers of participants are needed to confirm the findings. The clinical utility of our findings remains uncertain. It is possible that a high SF WBC count within the normal range may identify persons more likely to benefit from an IA steroid injection and even from other treatments targeted to joint inflammation. Our results highlight the need for further research to assess the potential value of SF WBC count in OA. SF WBC count may be an overlooked, yet easily measurable (16) , marker of OA disease severity or even a predictor of treatment response. These findings may have important implications both in the design of future research studies and in clinical practice.
